Loading insider details...
Beta
Latest Form 4 (Sep 9, 2026): Sale of 38,500 TRDA shares, $273.7K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 9, 2026 | Entrada Therapeutics, Inc. (TRDA) | Sale | 38,500 | $273.7K |
| Sep 3, 2026 | Entrada Therapeutics, Inc. (TRDA) | Sale | 29,088 | $205.4K |
| Aug 31, 2026 | Entrada Therapeutics, Inc. (TRDA) | Sale | 38,922 | $280.2K |
| Aug 27, 2026 | Entrada Therapeutics, Inc. (TRDA) | Sale | 21,623 | $158.7K |
| Jan 14, 2026 | Aktis Oncology, Inc. (AKTS) | Conversion | 1,314,262 | n/a |
| Dec 12, 2024 | Entrada Therapeutics, Inc. (TRDA) | Sale | 22,935 | $476.4K |
| Nov 4, 2021 | Entrada Therapeutics, Inc. (TRDA) | Conversion | 3,816,760 | n/a |
| Sep 23, 2020 | Dyne Therapeutics, Inc. (DYN) | Conversion | 4,614,943 | n/a |